Mount Yale Investment Advisors LLC Sells 3,204 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Mount Yale Investment Advisors LLC cut its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 39.0% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,004 shares of the company’s stock after selling 3,204 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Vaxcyte were worth $342,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Vaxcyte by 15.2% during the first quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock valued at $665,152,000 after purchasing an additional 1,284,883 shares during the period. Capital Research Global Investors increased its position in shares of Vaxcyte by 20.4% during the first quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock valued at $282,839,000 after purchasing an additional 700,414 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Vaxcyte by 18.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company’s stock valued at $216,966,000 after buying an additional 498,359 shares in the last quarter. Westfield Capital Management Co. LP boosted its stake in Vaxcyte by 9.0% in the 1st quarter. Westfield Capital Management Co. LP now owns 1,586,095 shares of the company’s stock valued at $108,346,000 after buying an additional 130,502 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in Vaxcyte by 12.7% in the 4th quarter. Franklin Resources Inc. now owns 1,076,920 shares of the company’s stock valued at $67,631,000 after buying an additional 120,985 shares in the last quarter. 96.78% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $74.99, for a total transaction of $599,920.00. Following the completion of the transaction, the chief financial officer now directly owns 95,679 shares of the company’s stock, valued at $7,174,968.21. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $74.99, for a total transaction of $599,920.00. Following the completion of the transaction, the chief financial officer now directly owns 95,679 shares of the company’s stock, valued at $7,174,968.21. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Elvia Cowan sold 5,000 shares of the company’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $80.00, for a total value of $400,000.00. Following the transaction, the senior vice president now directly owns 12,723 shares of the company’s stock, valued at $1,017,840. The disclosure for this sale can be found here. Insiders sold 103,766 shares of company stock worth $7,923,441 over the last ninety days. 3.10% of the stock is currently owned by corporate insiders.

Vaxcyte Price Performance

Vaxcyte stock traded down $1.17 on Monday, reaching $82.88. The company’s stock had a trading volume of 495,497 shares, compared to its average volume of 786,014. The business’s fifty day moving average price is $75.87 and its 200 day moving average price is $70.74. Vaxcyte, Inc. has a twelve month low of $44.20 and a twelve month high of $87.71.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Wednesday, May 8th. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.28. Equities research analysts forecast that Vaxcyte, Inc. will post -3.93 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research note on Thursday, June 20th. Needham & Company LLC reissued a “buy” rating and issued a $95.00 price objective on shares of Vaxcyte in a research note on Friday, June 28th.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.